BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C, Trerotoli P, Giannelli G, Manas D, Reeves H. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 2008;8:200. [PMID: 18638391 DOI: 10.1186/1471-2407-8-200] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Wu M, Liu Z, Li X, Zhang A, Li N. Dynamic Changes in Serum Markers and Their Utility in the Early Diagnosis of All Stages of Hepatitis B-Associated Hepatocellular Carcinoma. Onco Targets Ther. 2020;13:827-840. [PMID: 32095079 DOI: 10.2147/ott.s229835] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
2 Shen J, Sun H, Meng Q, Yin Q, Zhang Z, Yu H, Li Y. Simultaneous inhibition of tumor growth and angiogenesis for resistant hepatocellular carcinoma by co-delivery of sorafenib and survivin small hairpin RNA. Mol Pharm 2014;11:3342-51. [PMID: 24495194 DOI: 10.1021/mp4006408] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
3 Yu J, Wang ZJ, Chen LH, Dong WZ. Diagnostic value of serum squamous cell carcinoma antigen for hepatocellular carcinoma: a systematic review and meta-analysis. Scand J Clin Lab Invest 2017;77:8-14. [PMID: 27762143 DOI: 10.1080/00365513.2016.1238504] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
4 Jeon Y, Jang ES, Choi YS, Kim JW, Jeong SH. Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis. Clin Mol Hepatol. 2016;22:359-365. [PMID: 27729630 DOI: 10.3350/cmh.2016.0033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
5 Salama SM, Bilgen M, Al Rashdi AS, Abdulla MA. Efficacy of Boesenbergia rotunda Treatment against Thioacetamide-Induced Liver Cirrhosis in a Rat Model. Evid Based Complement Alternat Med 2012;2012:137083. [PMID: 22988470 DOI: 10.1155/2012/137083] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
6 Fang M, Zhao YP, Zhou FG, Lu LG, Qi P, Wang H, Zhou K, Sun SH, Chen CY, Gao CF. N-glycan based models improve diagnostic efficacies in hepatitis B virus-related hepatocellular carcinoma. Int J Cancer. 2010;127:148-159. [PMID: 19904744 DOI: 10.1002/ijc.25030] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
7 Liu XF, Hu ZD, Liu XC, Cao Y, Ding CM, Hu CJ. Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Biochem. 2014;47:196-200. [PMID: 24362268 DOI: 10.1016/j.clinbiochem.2013.12.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
8 Gray J, Chattopadhyay D, Beale GS, Patman GL, Miele L, King BP, Stewart S, Hudson M, Day CP, Manas DM. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer. 2009;9:271. [PMID: 19656391 DOI: 10.1186/1471-2407-9-271] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
9 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
10 Su TH, Peng CY, Chang SH, Tseng TC, Liu CJ, Chen CL, Liu CH, Yang HC, Chen PJ, Kao JH. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. J Formos Med Assoc 2021:S0929-6646(21)00361-2. [PMID: 34452785 DOI: 10.1016/j.jfma.2021.08.003] [Reference Citation Analysis]
11 Yin Q, Wang Y, Zheng C, Liu Y, Chen Z, Lu F, Huang G. Effects of two genes coding squamous cell carcinoma antigen on the diagnosis and treatment of cervical squamous cell carcinoma. Pak J Med Sci 2014;30:282-6. [PMID: 24772127 DOI: 10.12669/pjms.302.4374] [Reference Citation Analysis]
12 Tomoda T, Nouso K, Miyahara K, Kobayashi S, Kinugasa H, Toyosawa J, Hagihara H, Kuwaki K, Onishi H, Nakamura S. Prognotic impact of serum follistatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28:1391-1396. [PMID: 23432377 DOI: 10.1111/jgh.12167] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
13 Shiraki T, Ishizuka M, Kubota K, Kato M, Matsumoto T, Mori S, Shimizu T, Aoki T. An elevated neutrophil-to-lymphocyte ratio predicts a poor postoperative survival in primary hepatocellular carcinoma patients with a normal preoperative serum level of alpha-fetoprotein. Surg Today. 2019;49:661-669. [PMID: 30806789 DOI: 10.1007/s00595-019-01781-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. Duration of hepatic vascular inflow clamping and survival after liver resection for hepatocellular carcinoma. Br J Surg 2011;98:1284-90. [PMID: 21633950 DOI: 10.1002/bjs.7567] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
15 Wu CX, Liu QM, Zhao XL, Wang F, Xu DK, He W. An antibody microarray assay for screening serum biomarkers for liver cancer. Shijie Huaren Xiaohua Zazhi 2010; 18(31): 3378-3383 [DOI: 10.11569/wcjd.v18.i31.3378] [Reference Citation Analysis]
16 Kinukawa H, Shirakawa T, Yoshimura T. Epitope characterization of an anti-PIVKA-II antibody and evaluation of a fully automated chemiluminescent immunoassay for PIVKA-II. Clinical Biochemistry 2015;48:1120-5. [DOI: 10.1016/j.clinbiochem.2015.08.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
17 Haruyama Y, Kataoka H. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 275-283 [PMID: 26755876 DOI: 10.3748/wjg.v22.i1.275] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 51] [Article Influence: 9.5] [Reference Citation Analysis]
18 Ismail MH. Glypican-3-Expressing Hepatocellular Carcinoma in a Non-Cirrhotic Patient with Nonalcoholic Steatohepatitis: Case Report and Literature Review. Gastroenterology Res 2010;3:223-8. [PMID: 27957002 DOI: 10.4021/gr224w] [Reference Citation Analysis]
19 Bettini S, Bordigato E, Milan G, Dal Pra' C, Favaretto F, Belligoli A, Sanna M, Serra R, Foletto M, Prevedello L, Busetto L, Fassina G, Vettor R, Fabris R. SCCA-IgM as a Potential Biomarker of Non-Alcoholic Fatty Liver Disease in Patients with Obesity, Prediabetes and Diabetes Undergoing Sleeve Gastrectomy. Obes Facts 2019;12:291-306. [PMID: 31104052 DOI: 10.1159/000499717] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Yasuda E, Kumada T, Toyoda H, Kaneoka Y, Maeda A, Okuda S, Yoshimi N, Kozawa O. Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma. Hepatol Res. 2010;40:477-485. [PMID: 20374302 DOI: 10.1111/j.1872-034x.2010.00624.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
21 Tacke F, Kanig N, En-Nia A, Kaehne T, Eberhardt CS, Shpacovitch V, Trautwein C, Mertens PR. Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease. BMC Cancer 2011;11:185. [PMID: 21595987 DOI: 10.1186/1471-2407-11-185] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
22 Chávez-tapia NC, Méndez-sánchez N, Uribe M. Role of nonalcoholic fatty liver disease in hepatocellular carcinoma. Annals of Hepatology 2009;8:S34-9. [DOI: 10.1016/s1665-2681(19)31824-1] [Cited by in Crossref: 12] [Article Influence: 0.9] [Reference Citation Analysis]
23 Salama SM, Ibrahim IAA, Shahzad N, Al-Ghamdi S, Ayoub N, AlRashdi AS, Abdulla MA, Salehen N, Bilgen M. Hepatoprotectivity of Panduratin A against liver damage: In vivo demonstration with a rat model of cirrhosis induced by thioacetamide. APMIS 2018;126:710-21. [PMID: 30058214 DOI: 10.1111/apm.12878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
24 Miura M, Fujinami N, Shimizu Y, Mizuno S, Saito K, Suzuki T, Konishi M, Takahashi S, Gotohda N, Suto K, Yoshida T, Nakatsura T. Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery. Oncol Lett 2020;19:2657-66. [PMID: 32218816 DOI: 10.3892/ol.2020.11371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
25 Balaceanu LA. Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis. World J Clin Cases 2019; 7(12): 1367-1382 [PMID: 31363465 DOI: 10.12998/wjcc.v7.i12.1367] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
26 Jia X, Liu J, Gao Y, Huang Y, Du Z. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: A systematic review with meta-analysis. Arch Med Res. 2014;45:580-588. [PMID: 25446613 DOI: 10.1016/j.arcmed.2014.11.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
27 Sohn A, Kim H, Yu SJ, Yoon JH, Kim Y. A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma. Anal Bioanal Chem 2017;409:2829-38. [PMID: 28168546 DOI: 10.1007/s00216-017-0227-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
28 Feng X, Song P, Bie P, Jiang P, Ma K, Li X, Wang S, Wang Z, Tang W, Zheng S. Des-γ-Carboxyprothrombin Plasma Level in Diagnosis of Hepatocellular Carcinoma in a Chinese Population Undergoing Surgery. Med Sci Monit 2016;22:1663-72. [PMID: 27187589 DOI: 10.12659/msm.895483] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
29 Aydin Y, Koksal AR, Thevenot P, Chava S, Heidari Z, Lin D, Sandow T, Moroz K, Parsi MA, Scott J, Cohen A, Dash S. Experimental Validation of Novel Glypican 3 Exosomes for the Detection of Hepatocellular Carcinoma in Liver Cirrhosis. JHC 2021;Volume 8:1579-96. [DOI: 10.2147/jhc.s327339] [Reference Citation Analysis]
30 Sharma B, Srinivasan R, Chawla YK, Kapil S, Saini N, Singla B, Chakraborthy A, Kalra N, Duseja A, Dhiman RK. Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population. Hepatol Int. 2010;4:569-576. [PMID: 21063479 DOI: 10.1007/s12072-010-9186-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
31 Taura N, Ichikawa T, Miyaaki H, Ozawa E, Tsutsumi T, Tsuruta S, Kato Y, Goto T, Kinoshita N, Fukushima M, Kato H, Ohata K, Ohba K, Masuda J, Hamasaki K, Yatsuhashi H, Nakao K. Frequency of elevated biomarkers in patients with cryptogenic hepatocellular carcinoma. Med Sci Monit 2013;19:742-50. [PMID: 24008520 DOI: 10.12659/MSM.889361] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
32 Chen H, Chen S, Li S, Chen Z, Zhu X, Dai M, Kong L, Lv X, Huang Z, Qin X. Combining des-gamma-carboxyprothrombin and alpha-fetoprotein for hepatocellular carcinoma diagnosing: an update meta-analysis and validation study. Oncotarget 2017;8:90390-401. [PMID: 29163838 DOI: 10.18632/oncotarget.20153] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
33 Li J, Wang T, Jin B, Li W, Wang Z, Zhang H, Song Y, Li N. Diagnosis accuracy of serum glypican-3 level in patients with hepatocellular carcinoma: A systematic review with meta-analysis. Int J Biol Markers. 2018;1724600818784409. [PMID: 30071741 DOI: 10.1177/1724600818784409] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
34 Hagag NA, Ali YBM, Elsharawy AA, Talaat RM. Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression. J Gastrointest Cancer. 2020;51:234-241. [PMID: 31028536 DOI: 10.1007/s12029-019-00234-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
35 Kamel MM, Saad MF, Mahmoud AA, Edries AA, Abdel-moneim AS. Evaluation of serum PIVKA-II and MIF as diagnostic markers for HCV/HBV induced hepatocellular carcinoma. Microbial Pathogenesis 2014;77:31-5. [DOI: 10.1016/j.micpath.2014.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
36 Inagaki Y, Tang W, Makuuchi M, Hasegawa K, Sugawara Y, Kokudo N. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin. Liver Int. 2011;31:22-35. [PMID: 20874725 DOI: 10.1111/j.1478-3231.2010.02348.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 5.5] [Reference Citation Analysis]
37 Herrera B, Addante A, Sánchez A. BMP Signalling at the Crossroad of Liver Fibrosis and Regeneration. Int J Mol Sci 2017;19:E39. [PMID: 29295498 DOI: 10.3390/ijms19010039] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
38 De J, Shen Y, Qin J, Feng L, Wang Y, Yang L. A Systematic Review of Des-γ-Carboxy Prothrombin for the Diagnosis of Primary Hepatocellular Carcinoma. Medicine (Baltimore). 2016;95:e3448. [PMID: 27124038 DOI: 10.1097/md.0000000000003448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Moldogazieva NT, Mokhosoev IM, Zavadskiy SP, Terentiev AA. Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine. Biomedicines 2021;9:159. [PMID: 33562077 DOI: 10.3390/biomedicines9020159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Archer KJ, Mas VR, David K, Maluf DG, Bornstein K, Fisher RA. Identifying genes for establishing a multigenic test for hepatocellular carcinoma surveillance in hepatitis C virus-positive cirrhotic patients. Cancer Epidemiol Biomarkers Prev 2009;18:2929-32. [PMID: 19861515 DOI: 10.1158/1055-9965.EPI-09-0767] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
41 Waidely E, Al-Yuobi AR, Bashammakh AS, El-Shahawi MS, Leblanc RM. Serum protein biomarkers relevant to hepatocellular carcinoma and their detection. Analyst. 2016;141:36-44. [PMID: 26606739 DOI: 10.1039/c5an01884f] [Cited by in Crossref: 40] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
42 Kreidl E, Öztürk D, Metzner T, Berger W, Grusch M. Activins and follistatins: Emerging roles in liver physiology and cancer. World J Hepatol 2009; 1(1): 17-27 [PMID: 21160961 DOI: 10.4254/wjh.v1.i1.17] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
43 Yu R, Xiang X, Tan Z, Zhou Y, Wang H, Deng G. Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients. Sci Rep 2016;6:35050. [PMID: 27731353 DOI: 10.1038/srep35050] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
44 Xu D, Su C, Sun L, Gao Y, Li Y. Performance of Serum Glypican 3 in Diagnosis of Hepatocellular Carcinoma: A meta-analysis. Ann Hepatol. 2019;18:58-67. [PMID: 31113610 DOI: 10.5604/01.3001.0012.7863] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
45 Tiniakos DG, Maurício J, Reeves HL. Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View. Adv Exp Med Biol 2018;1032:55-69. [PMID: 30362090 DOI: 10.1007/978-3-319-98788-0_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Archer KJ, Mas VR, Maluf DG, Fisher RA. High-throughput assessment of CpG site methylation for distinguishing between HCV-cirrhosis and HCV-associated hepatocellular carcinoma. Mol Genet Genomics. 2010;283:341-349. [PMID: 20165882 DOI: 10.1007/s00438-010-0522-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
47 Jia X, Gao Y, Zhai D, Liu J, Cai J, Wang Y, Jing L, Du Z. Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma. Technol Cancer Res Treat 2016;15:780-6. [DOI: 10.1177/1533034615605248] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
48 Wang L, Huang J, Jiang M, Zheng X. AFP computational secreted network construction and analysis between human hepatocellular carcinoma (HCC) and no-tumor hepatitis/cirrhotic liver tissues. Tumour Biol. 2010;31:417-425. [PMID: 20532728 DOI: 10.1007/s13277-010-0050-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
49 Zhou S, O'Gorman MR, Yang F, Andresen K, Wang L. Glypican 3 as a Serum Marker for Hepatoblastoma. Sci Rep 2017;7:45932. [PMID: 28378832 DOI: 10.1038/srep45932] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
50 Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer. 2013;2:31-39. [PMID: 24159594 DOI: 10.1159/000346220] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
51 Zhao Y, Gao Q, Pei L, Wang C, Jin L, Liao F. Current Status and Future Prospects of Biomarkers in the Diagnosis of Hepatocellular Carcinoma. Int J Biol Markers 2017;32:361-9. [DOI: 10.5301/ijbm.5000299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
52 Lai Q, Melandro F, Pinheiro RS, Donfrancesco A, Fadel BA, Levi Sandri GB, Rossi M, Berloco PB, Frattaroli FM. Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again. Int J Hepatol. 2012;2012:893103. [PMID: 22792474 DOI: 10.1155/2012/893103] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
53 Unić A, Derek L, Duvnjak M, Patrlj L, Rakić M, Kujundžić M, Renjić V, Štoković N, Dinjar P, Jukic A, Grgurević I. Diagnostic specificity and sensitivity of PIVKAII, GP3, CSTB, SCCA1 and HGF for the diagnosis of hepatocellular carcinoma in patients with alcoholic liver cirrhosis. Ann Clin Biochem 2018;55:355-62. [DOI: 10.1177/0004563217726808] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
54 Fransvea E, Trerotoli P, Sacco R, Bernabucci V, Milella M, Napoli N, Mazzocca A, Renna E, Quaranta M, Angarano G. SCCA-IC serum levels are predictive of clinical response in HCV chronic hepatitis to antiviral therapy: a multicentric prospective study. J Viral Hepat. 2012;19:704-710. [PMID: 22967101 DOI: 10.1111/j.1365-2893.2012.01604.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
55 Wray CJ, Ko TC, Tan FK. Secondary use of existing public microarray data to predict outcome for hepatocellular carcinoma. Journal of Surgical Research 2014;188:137-42. [DOI: 10.1016/j.jss.2013.12.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
56 Luo FB, Zhang KH. Advances in the relationship between glypican-3 and primary hepatic carcinoma. Shijie Huaren Xiaohua Zazhi 2010; 18(2): 155-159 [DOI: 10.11569/wcjd.v18.i2.155] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Li X, Lu J, Ren H, Chen T, Gao L, DI L, Song Z, Zhang Y, Yang T, Thakur A, Zhou SF, Yin Y, Chen M. Combining multiple serum biomarkers in tumor diagnosis: A clinical assessment. Mol Clin Oncol 2013;1:153-60. [PMID: 24649139 DOI: 10.3892/mco.2012.23] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
58 Chang NW, Dai HJ, Shih YY, Wu CY, Dela Rosa MAC, Obena RP, Chen YJ, Hsu WL, Oyang YJ. Biomarker identification of hepatocellular carcinoma using a methodical literature mining strategy. Database (Oxford) 2017;2017:bax082. [PMID: 31725857 DOI: 10.1093/database/bax082] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
59 Wang T, Li C, Liu Y, Li T, Zhang J, Sun Y. Inhibition effects of Chinese cabbage powder on aflatoxin B1-induced liver cancer. Food Chem 2015;186:13-9. [PMID: 25976785 DOI: 10.1016/j.foodchem.2015.02.138] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
60 Rohrbeck A, Borlak J. Cancer genomics identifies regulatory gene networks associated with the transition from dysplasia to advanced lung adenocarcinomas induced by c-Raf-1. PLoS One 2009;4:e7315. [PMID: 19812696 DOI: 10.1371/journal.pone.0007315] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
61 Banaudha KK, Verma M. Epigenetic biomarkers in liver cancer. Methods Mol Biol 2015;1238:65-76. [PMID: 25421655 DOI: 10.1007/978-1-4939-1804-1_4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
62 Tang X, Li H, Yan L, Zhou L, Chen E, Liu M, Zhang D, Tang H. Diagnostic value of PIVKA-II in detecting hepatocellular carcinoma. Future Virology 2017;12:259-67. [DOI: 10.2217/fvl-2017-0017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
63 Yang SL, Fang X, Huang ZZ, Liu XJ, Xiong ZF, Liu P, Yao HY, Li CH. Can serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma? A meta-analysis of the literature. Dis Markers. 2014;2014:127831. [PMID: 25378766 DOI: 10.1155/2014/127831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
64 El-Abd N, Fawzy A, Elbaz T, Hamdy S. Evaluation of annexin A2 and as potential biomarkers for hepatocellular carcinoma. Tumour Biol. 2016;37:211-216. [PMID: 26189841 DOI: 10.1007/s13277-015-3524-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
65 Wang Z, Bai Z, Zhang H, Huan T, Li J, Du X, Zhang J. Growth potential of human hepatocarcinoma cells in the liver of neonatal immunocompetent mice and its relation to immunological tolerance. Progress in Natural Science 2009;19:705-12. [DOI: 10.1016/j.pnsc.2008.08.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
66 Haruyama Y, Yorita K, Yamaguchi T, Kitajima S, Amano J, Ohtomo T, Ohno A, Kondo K, Kataoka H. High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy. Int J Cancer. 2015;137:1643-1651. [PMID: 25784484 DOI: 10.1002/ijc.29518] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
67 Salama SM, Abdulla MA, AlRashdi AS, Ismail S, Alkiyumi SS, Golbabapour S. Hepatoprotective effect of ethanolic extract of Curcuma longa on thioacetamide induced liver cirrhosis in rats. BMC Complement Altern Med. 2013;13:56. [PMID: 23496995 DOI: 10.1186/1472-6882-13-56] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 7.2] [Reference Citation Analysis]
68 Xu P, Xu CF, Wan XY, Yu CH, Shen C, Chen P, Xu GY, Li YM. Association between serum alpha-fetoprotein levels and fatty liver disease: A cross-sectional study. World J Gastroenterol 2014; 20(33): 11865-11870 [PMID: 25206293 DOI: 10.3748/wjg.v20.i33.11865] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
69 Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol 2020;26:261-79. [PMID: 32536045 DOI: 10.3350/cmh.2020.0032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
70 Caviglia GP, Armandi A, Rosso C, Gaia S, Aneli S, Rolle E, Abate ML, Olivero A, Nicolosi A, Guariglia M, Ribaldone DG, Carucci P, Saracco GM, Bugianesi E. Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Cancers (Basel) 2021;13:2305. [PMID: 34064999 DOI: 10.3390/cancers13102305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Xu C, Yan Z, Zhou L, Wang Y. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2013;139:1417-1424. [PMID: 23743582 DOI: 10.1007/s00432-013-1458-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
72 Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res. 2013;1:10. [PMID: 24252133 DOI: 10.1186/2050-7771-1-10] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
73 Montagnana M, Danese E, Lippi G. Squamous cell carcinoma antigen in hepatocellular carcinoma: Ready for the prime time? Clin Chim Acta. 2015;445:161-166. [PMID: 25840050 DOI: 10.1016/j.cca.2015.03.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
74 Viggiani V, Palombi S, Gennarini G, D’ettorre G, De Vito C, Angeloni A, Frati L, Anastasi E. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients. Scandinavian Journal of Gastroenterology 2016;51:1257-62. [DOI: 10.1080/00365521.2016.1183705] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
75 Wu CS, Lee TY, Chou RH, Yen CJ, Huang WC, Wu CY, Yu YL. Development of a highly sensitive glycan microarray for quantifying AFP-L3 for early prediction of hepatitis B virus-related hepatocellular carcinoma. PLoS One. 2014;9:e99959. [PMID: 24927126 DOI: 10.1371/journal.pone.0099959] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
76 Omran MM, Emran TM, Farid K, Eltaweel FM, Omar MA, Bazeed FB. An Easy and Useful Noninvasive Score Based on α-1-acid Glycoprotein and C-Reactive Protein for Diagnosis of Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus Infection. J Immunoassay Immunochem 2016;37:273-88. [PMID: 26685049 DOI: 10.1080/15321819.2015.1132229] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
77 Fatica EM, Larson BJ, Algeciras-Schimnich A, Bornhorst JA. Performance characteristics of the BRAHMS KRYPTOR automated squamous cell carcinoma antigen assay. J Immunol Methods 2022;:113257. [PMID: 35304118 DOI: 10.1016/j.jim.2022.113257] [Reference Citation Analysis]
78 Song P, Feng X, Zhang K, Song T, Ma K, Kokudo N, Dong J, Tang W. Perspectives on using des-γ-carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in China. Hepatobiliary Surg Nutr. 2013;2:227-231. [PMID: 24570947 DOI: 10.3978/j.issn.2304-3881.2013.08.11] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
79 Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma: A systematic review. Hepatol Res. 2014;44:E11-E25. [PMID: 23834468 DOI: 10.1111/hepr.12201] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
80 Li SL, Gao YT, Shan SG, Liang ZH, Zhai DK, Jing L, Liu T, Du Z, Wang YJ. Expression of SCCA1 in human hepatocellular carcinoma and its clinical significance. Shijie Huaren Xiaohua Zazhi 2014; 22(7): 1015-1021 [DOI: 10.11569/wcjd.v22.i7.1015] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
81 Jang ES, Jeong SH, Kim JW, Choi YS, Leissner P, Brechot C. Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma. PLoS One. 2016;11:e0151069. [PMID: 26986465 DOI: 10.1371/journal.pone.0151069] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
82 van Ginkel WG, Pennings JP, van Spronsen FJ. Liver Cancer in Tyrosinemia Type 1. Adv Exp Med Biol 2017;959:101-9. [PMID: 28755188 DOI: 10.1007/978-3-319-55780-9_9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
83 Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL;  HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493-502. [PMID: 19852963 DOI: 10.1053/j.gastro.2009.10.031] [Cited by in Crossref: 338] [Cited by in F6Publishing: 303] [Article Influence: 26.0] [Reference Citation Analysis]
84 Fu Y, Chung FL. Oxidative stress and hepatocarcinogenesis. Hepatoma Res. 2018;4. [PMID: 30761356 DOI: 10.20517/2394-5079.2018.29] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]